Search clinical trials for: CC-292

Total 1583 results

Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia
National Cancer Institute (NCI)

Completed

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Brain and Central Nervous System Tumors

United States
Boston Medical Center

Completed

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene

Active, not recruiting

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Astrocytoma

United States, Spain
Celgene

Active, not recruiting

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

France, Canada, United States, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Jean Edward

Completed

Coverage and Cost-of-Care (CC) Links- Financial Navigation Program (CC Links)

Financial Stress | Survivorship | Hematologic Cancer

United States
Benjamin Rose Institute on Aging

Withdrawn

SHARE for Persons With Chronic Conditions and Their Family Caregivers (SHARE-CC)

Family Caregivers | Chronic Health Conditions

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Sun Yat-sen University
Ministry of Health, China; Xidian University

Completed

Validation of the Utility of Rare Disease Intelligence Platform

Cataract | Artificial Intelligence

China
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)

Soft Tissue Sarcoma | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Infantile Fibrosarcoma | Infantile Myofibromatosis

United States, Australia, Japan, Canada, Germany, Korea, Republic of, France, Spain, United Kingdom, Denmark, Italy
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark
University of Houston

Recruiting

Dual Use Approach Bias Training for Nicotine Addiction

Tobacco Smoking | Electronic Cigarette Use | Substance Use

United States
Kaiser Clinic and Hospital

Completed

Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity

Obesity | Metabolic Syndrome

Brazil
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Melanoma

United States, Canada
EarliTec Diagnostics, Inc
Marcus Autism Center

Recruiting

Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD) For Children Ages 31-84 Months (MEASURE-ASD2)

Autism Spectrum Disorder | Autism

United States
University of Alberta

Withdrawn

Does Higher (100% Oxygen) Versus Lower (21% Oxygen) During CC+SI During CPR of Asphyxiated Newborns Improve Time to ROSC (SURV1VE-O2)

Bradycardia Neonatal | Birth Asphyxia | Heart; Arrest, Newborn

Canada
Celgene

Terminated

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis (AS SpA axSpA)

Spondylitis, Ankylosing

United States, China, Czechia, Germany, Poland, Romania, Spain, Turkey
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Smoking

Poland
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Healthy Volunteers

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Celgene

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Terminated

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Psoriasis | Healthy Volunteers

Germany
Celgene

No longer available

Expanded Access for Marizomib

Solid Tumor

United States
Celgene

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

Healthy Volunteer

United Kingdom
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
University of Washington
Patient-Centered Outcomes Research Institute

Completed

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (MS-CARE)

Depression | Pain | Multiple Sclerosis

United States
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
Celgene
The Leukemia and Lymphoma Society

Completed

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | B Cell Non-Hodgkin's Lymphoma

United States
Amgen

Completed

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Asthma

United States
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Healthy Volunteer

United States

3

Subscribe